TrialFuture oncology (London, England)2026
IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.
Lakshmi Nayak et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.